Estimates of Effects, Credible Intervals, and Certainty of the Evidence for the Maintenance of Surgically Induced Remission in Crohn’s Disease: Benefits
| Total studies: 12 RCTs Total participants: 1128 . | Relative effect (95% CI) . | Quality of Evidence (GRADE) . | Ranking (95% CrI) ** . |
|---|---|---|---|
| Outcome: Clinical relapse | |||
| Adalimumab (3 RCTs; 37 participants) | HR 0.10 (0.01–0.32) | Low | 1 (1 of 2) |
| Infliximab (2 RCTs; 21 participants) | HR 0.24 (0.01–1.20) | Low | 2 (1 to 6) |
| Antibiotics (2 RCTs; 57 participants) | HR 0.80 (0.33–1.65) | Very low | 3 (2 to 7) |
| Purine analogues (4 RCTs; 164 participants) | HR 0.85 (0.33–1.61) | Very low | 4 (3 to 7) |
| Probiotics (3 RCTs; 108 participants) | HR 1.20 (0.62–2.19) | Very low | 6 (3 to 7) |
| 5-ASA (3 RCTs; 237 participants) | HR 1.22 (0.61–2.18) | Very low | 6 (3 to 7) |
| Placebo (8 RCTs; 507 participants) | Reference comparator | No estimate | 5 (3 to 7) |
| Total studies: 12 RCTs Total participants: 1128 . | Relative effect (95% CI) . | Quality of Evidence (GRADE) . | Ranking (95% CrI) ** . |
|---|---|---|---|
| Outcome: Clinical relapse | |||
| Adalimumab (3 RCTs; 37 participants) | HR 0.10 (0.01–0.32) | Low | 1 (1 of 2) |
| Infliximab (2 RCTs; 21 participants) | HR 0.24 (0.01–1.20) | Low | 2 (1 to 6) |
| Antibiotics (2 RCTs; 57 participants) | HR 0.80 (0.33–1.65) | Very low | 3 (2 to 7) |
| Purine analogues (4 RCTs; 164 participants) | HR 0.85 (0.33–1.61) | Very low | 4 (3 to 7) |
| Probiotics (3 RCTs; 108 participants) | HR 1.20 (0.62–2.19) | Very low | 6 (3 to 7) |
| 5-ASA (3 RCTs; 237 participants) | HR 1.22 (0.61–2.18) | Very low | 6 (3 to 7) |
| Placebo (8 RCTs; 507 participants) | Reference comparator | No estimate | 5 (3 to 7) |
Abbreviations: 5-ASA, 5-aminosalicylic acid; CI, confidence interval; Crl, credible interval; GRADE, Grading of Recommendations, Assessment, Development and Evaluations; HR, hazard ratio; RCT, randomized control trial.
Estimates of Effects, Credible Intervals, and Certainty of the Evidence for the Maintenance of Surgically Induced Remission in Crohn’s Disease: Benefits
| Total studies: 12 RCTs Total participants: 1128 . | Relative effect (95% CI) . | Quality of Evidence (GRADE) . | Ranking (95% CrI) ** . |
|---|---|---|---|
| Outcome: Clinical relapse | |||
| Adalimumab (3 RCTs; 37 participants) | HR 0.10 (0.01–0.32) | Low | 1 (1 of 2) |
| Infliximab (2 RCTs; 21 participants) | HR 0.24 (0.01–1.20) | Low | 2 (1 to 6) |
| Antibiotics (2 RCTs; 57 participants) | HR 0.80 (0.33–1.65) | Very low | 3 (2 to 7) |
| Purine analogues (4 RCTs; 164 participants) | HR 0.85 (0.33–1.61) | Very low | 4 (3 to 7) |
| Probiotics (3 RCTs; 108 participants) | HR 1.20 (0.62–2.19) | Very low | 6 (3 to 7) |
| 5-ASA (3 RCTs; 237 participants) | HR 1.22 (0.61–2.18) | Very low | 6 (3 to 7) |
| Placebo (8 RCTs; 507 participants) | Reference comparator | No estimate | 5 (3 to 7) |
| Total studies: 12 RCTs Total participants: 1128 . | Relative effect (95% CI) . | Quality of Evidence (GRADE) . | Ranking (95% CrI) ** . |
|---|---|---|---|
| Outcome: Clinical relapse | |||
| Adalimumab (3 RCTs; 37 participants) | HR 0.10 (0.01–0.32) | Low | 1 (1 of 2) |
| Infliximab (2 RCTs; 21 participants) | HR 0.24 (0.01–1.20) | Low | 2 (1 to 6) |
| Antibiotics (2 RCTs; 57 participants) | HR 0.80 (0.33–1.65) | Very low | 3 (2 to 7) |
| Purine analogues (4 RCTs; 164 participants) | HR 0.85 (0.33–1.61) | Very low | 4 (3 to 7) |
| Probiotics (3 RCTs; 108 participants) | HR 1.20 (0.62–2.19) | Very low | 6 (3 to 7) |
| 5-ASA (3 RCTs; 237 participants) | HR 1.22 (0.61–2.18) | Very low | 6 (3 to 7) |
| Placebo (8 RCTs; 507 participants) | Reference comparator | No estimate | 5 (3 to 7) |
Abbreviations: 5-ASA, 5-aminosalicylic acid; CI, confidence interval; Crl, credible interval; GRADE, Grading of Recommendations, Assessment, Development and Evaluations; HR, hazard ratio; RCT, randomized control trial.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
